NSE: GLENMARK | BSE: 532296

Mid-range Performer

Download real time

2017.80 -67.40 (-3.23%)

58.20% Gain from 52W Low

720.8K NSE+BSE Volume

NSE 22 Sep, 2025 3:31 PM (IST)

56,942.5

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

03 Feb 2017

2017.80

-3.23%

Glenmark Pharmaceuticals

Buy: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 43% YoY to | 2535 crore (I-direct estimate: | 2239 crore) mainly due to 102% YoY growth in the US to | 1231 crore (Idirect estimate: | 865 crore) mainly due to gZetia exclusivity EBITDA margins improved 934 bps YoY to 30.2% (I-direct estimate:...

Number of FII/FPI investors decreased from 404 to 396 in Jun 2025 qtr

Glenmark Pharmaceuticals Ltd.

21 Dec 2016, 12:37PM

2017.80

-3.23%

Glenmark (Update): Thrust on innovation. Maintain NEUTRAL

Neutral: Glenmark Pharmaceuticals Ltd.

HDFC Securities

During the GNP analyst meet, the management rolled out its ten year strategic roadmap for the company. Going forward, the focal points for GNP will be complex generics, specialty products and novel candidates.

Glenmark Pharmaceuticals Ltd.'s price crossed below 50Day SMA today

Glenmark Pharmaceuticals Ltd.

06 Dec 2016

2017.80

-3.23%

Company Update:Glenmark Pharma.

Buy: Glenmark Pharmaceuticals Ltd.

Axis Direct

Our meeting with Mr. Glenn Saldanha (CMD, Glenmark Pharma) reaffirms our view that US, India and Russia (key businesses comprising ~70% of H1FY17 sales) have strong growth visibility which would help achieve FY19 EBITDA guidance of 23% (vs.20% in H1FY17).

Glenmark Pharmaceuticals Ltd.'s price crossed below 50Day SMA today

Glenmark Pharmaceuticals Ltd.

01 Nov 2016

2017.80

-3.23%

Glenmark Pharmaceuticals

Buy: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 19% YoY to | 2224 crore (I-direct estimate: | 2226 crore) mainly due to 29% YoY growth in the US to | 771 crore (Idirect estimate: | 762 crore). India business grew 11% YoY to | 675 crore (I-direct estimate: | 596 crore) EBITDA margins declined 126 bps YoY to 20.2% (vs. I-direct estimate: 20.0%) due to higher other expenditure. EBITDA increased 12% YoY to | 449 crore (I-direct estimate: | 445 crore) Net profit increased 12% YoY to | 224 crore, (I-direct estimate: | 263...

Glenmark Pharmaceuticals Ltd. has gained 33.21% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

29 Oct 2016

2017.80

-3.23%

Glenmark (2QFY17): gZetia launch priced in. Maintain NEUTRAL

Neutral: Glenmark Pharmaceuticals Ltd.

Target

HDFC Securities

Buoyant performance of the US, Russia/CIS and API segments led to a 16% YoY growth in the top line. However, a sharp increase (up 21%YoY) in the staff cost due to incremental incentives kept EBITDA margins below expectations at 18.3% in 2Q. PAT growth too was sluggish at 11% YoY only.

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.

Glenmark Pharmaceuticals Ltd.

28 Oct 2016

2017.80

-3.23%

Glenmark - 2QFY17 Result Update

Hold: Glenmark Pharmaceuticals Ltd.

Target

Reliance Securities

US Business: Improvement in US business (up 25% yoy & 10% qoq) is driven by multiple factors such as: strong gain in market share in gCrestor, ramp-up in recently launched products, gMupirocin sales improvement, strong traction in derma (new launches: T-Cream, gDiclofenac, gLidocaine) and other products. Management believes that the price erosion in base business stood at 10% on account of increased approvals by the US FDA. It further expects most future launches (till FY19E) would be from derma segment, as it believes that post FY19E, the Company will see more launches in complex generic space (injectables)....

Glenmark Pharmaceuticals Ltd.'s price crossed below 50Day SMA today

Glenmark Pharmaceuticals Ltd.

28 Oct 2016

2017.80

-3.23%

Result Review of Glenmark Pharmaceuticals Ltd

Accumulate: Glenmark Pharmaceuticals Ltd.

IDBI Capital

Total revenues for Q2FY17 were up 16.48%/14.4% YoY/QoQ at Rs22.2 bn in-line with our estimates triggered by growth across key geographies, however, entire EM ex-India continued to get impacted on account of currency devaluation . EBITDA margin declined 97bps YoY and up 67bps QoQ from 21.1% in Q2FY16 to 20.2% in current quarter mainly due to the continuing pricing pressure in the base business. It was down 120bps against our guidance was due mainly to higher than expected Staff Costs (payment of variable pays, annual increments and addition in employees). But we believe an improvement in the margins attributable also to the better product mix....

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

16 Aug 2016

2017.80

-3.23%

Glenmark (1QFY17): Good, not great. NEUTRAL

Neutral: Glenmark Pharmaceuticals Ltd.

HDFC Securities

Glenmarks strong top line performance (16% YoY) and sequential improvement in profitability led to 24% YoY earnings growth in 1QFY17. Revenues increased to Rs 18.8bn with US business growing at 24% YoY.

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.

Is Glenmark Pharmaceuticals Ltd. worth buying?

571 Votes:

Buy 79.33%

Sell 13.66%

Hold 7.01%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf